At six months post-grafting surgery with NVDX3, x-rays demonstrate that 90% of patients have reached, or are steadily progressing towards, complete bone ...
“ATX-01 is a very unique molecule – it was discovered and developed entirely in-house by ARTHEx scientists through years of engineering and execution, and we are excited about the potential of its ...
NORTH CHICAGO, IL, USA I October 17, 2024 I AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved VYALEV™ ...
Following successful Phase 1b completion, Clarametyx is initiating the Phase 2a portion to assess CMTX-101 as an adjunct to standard of care for chronic ...
PARIS, France I October 17, 2024 I Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to ...
PRINCETON, NJ, USA I October 15, 2024 I UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions ...
BETHESDA, MD & GAITHERSBURG, MD, USA I October 16 2024 I Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools ...